Advanced search
1 file | 438.92 KB Add to list

Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis

(2014) AIDS. 28(4). p.577-587
Author
Organization
Abstract
Background: Most antiretroviral drugs are metabolized by the liver; hepatic disease or liver damage as a result of hepatitis C virus (HCV) could impair this metabolism leading to an increased risk of drug toxicity. This study aimed to determine the risk of antiretroviral drug discontinuation among HCV/HIV coinfected patients. Methods: EuroSIDA patients taking combination antiretroviral therapy were included. Poisson regression identified factors associated with antiretroviral treatment discontinuation. Results: A total of 9535 HIV-positive patients with known HCV status were included (6939 HCVAb-negative; 2596 HCVAb-positive at baseline). Viremic HCV infection was associated with a 44% increased risk of antiretroviral drug discontinuation compared with aviremic infection [adjusted incidence rate ratio, aIRR: 1.44 (95% confidence interval, CI 1.22-1.69)]; this relationship was largest among nonnucleoside reverse transcriptase inhibitors [aIRR: 1.59 (95% CI 1.18-2.14)]. In the subset of 935 HIV-positive patients also HCV-positive or HBV-positive with plasma hyaluronic acid measured, hyaluronic acid more than 100 ng/ml was associated with a 37% increased risk of antiretroviral drug discontinuation [aIRR: 1.37 (95% CI 1.08-1.73) vs. hyaluronic acid <= 100 ng/ml] and the effect of HCV viremia became nonsignificant; the largest drug association was seen for protease inhibitors [aIRR: 1.40 (95% CI 1.04-1.89)]. Conclusion: HCV viremia and high levels of hyaluronic acid predict antiretroviral drug discontinuation. Evidence was also found to suggest a link between impaired liver function and protease inhibitor toxicity.
Keywords
HIV, treatment discontinuation, toxicity, TOXICITY, significant fibrosis, HEPATOTOXICITY, combination antiretroviral therapy, PATIENT/PHYSICIAN CHOICE, coinfection, INFECTED PATIENTS, HUMAN-IMMUNODEFICIENCY-VIRUS, NATURAL-HISTORY, PROTEASE INHIBITORS, DISEASE PROGRESSION, HIV, THERAPY, hyaluronic acid, hepatitis C virus

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 438.92 KB

Citation

Please use this url to cite or link to this publication:

MLA
Grint, Daniel, et al. “Increased Incidence of Antiretroviral Drug Discontinuation among Patients with Viremic Hepatitis C Virus Coinfection and High Hyaluronic Acid, a Marker of Liver Fibrosis.” AIDS, vol. 28, no. 4, 2014, pp. 577–87, doi:10.1097/QAD.0000000000000069.
APA
Grint, D., Peters, L., Rockstroh, J. K., De Wit, S., Mitsura, V. M., Knysz, B., … Vandekerckhove, L. (2014). Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS, 28(4), 577–587. https://doi.org/10.1097/QAD.0000000000000069
Chicago author-date
Grint, Daniel, Lars Peters, Juergen K Rockstroh, Stephane De Wit, Victor M Mitsura, Brygida Knysz, Court Pedersen, et al. 2014. “Increased Incidence of Antiretroviral Drug Discontinuation among Patients with Viremic Hepatitis C Virus Coinfection and High Hyaluronic Acid, a Marker of Liver Fibrosis.” AIDS 28 (4): 577–87. https://doi.org/10.1097/QAD.0000000000000069.
Chicago author-date (all authors)
Grint, Daniel, Lars Peters, Juergen K Rockstroh, Stephane De Wit, Victor M Mitsura, Brygida Knysz, Court Pedersen, Ole Kirk, Jens D Lundgren, Amanda Mocroft, the EuroSIDA Study group, and Linos Vandekerckhove. 2014. “Increased Incidence of Antiretroviral Drug Discontinuation among Patients with Viremic Hepatitis C Virus Coinfection and High Hyaluronic Acid, a Marker of Liver Fibrosis.” AIDS 28 (4): 577–587. doi:10.1097/QAD.0000000000000069.
Vancouver
1.
Grint D, Peters L, Rockstroh JK, De Wit S, Mitsura VM, Knysz B, et al. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS. 2014;28(4):577–87.
IEEE
[1]
D. Grint et al., “Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis,” AIDS, vol. 28, no. 4, pp. 577–587, 2014.
@article{4352259,
  abstract     = {{Background: Most antiretroviral drugs are metabolized by the liver; hepatic disease or liver damage as a result of hepatitis C virus (HCV) could impair this metabolism leading to an increased risk of drug toxicity. This study aimed to determine the risk of antiretroviral drug discontinuation among HCV/HIV coinfected patients.
Methods: EuroSIDA patients taking combination antiretroviral therapy were included. Poisson regression identified factors associated with antiretroviral treatment discontinuation.
Results: A total of 9535 HIV-positive patients with known HCV status were included (6939 HCVAb-negative; 2596 HCVAb-positive at baseline). Viremic HCV infection was associated with a 44% increased risk of antiretroviral drug discontinuation compared with aviremic infection [adjusted incidence rate ratio, aIRR: 1.44 (95% confidence interval, CI 1.22-1.69)]; this relationship was largest among nonnucleoside reverse transcriptase inhibitors [aIRR: 1.59 (95% CI 1.18-2.14)]. In the subset of 935 HIV-positive patients also HCV-positive or HBV-positive with plasma hyaluronic acid measured, hyaluronic acid more than 100 ng/ml was associated with a 37% increased risk of antiretroviral drug discontinuation [aIRR: 1.37 (95% CI 1.08-1.73) vs. hyaluronic acid <= 100 ng/ml] and the effect of HCV viremia became nonsignificant; the largest drug association was seen for protease inhibitors [aIRR: 1.40 (95% CI 1.04-1.89)].
Conclusion: HCV viremia and high levels of hyaluronic acid predict antiretroviral drug discontinuation. Evidence was also found to suggest a link between impaired liver function and protease inhibitor toxicity.}},
  author       = {{Grint, Daniel and Peters, Lars and Rockstroh, Juergen K and De Wit, Stephane and Mitsura, Victor M and Knysz, Brygida and Pedersen, Court and Kirk, Ole and Lundgren, Jens D and Mocroft, Amanda and EuroSIDA Study group, the and Vandekerckhove, Linos}},
  issn         = {{0269-9370}},
  journal      = {{AIDS}},
  keywords     = {{HIV,treatment discontinuation,toxicity,TOXICITY,significant fibrosis,HEPATOTOXICITY,combination antiretroviral therapy,PATIENT/PHYSICIAN CHOICE,coinfection,INFECTED PATIENTS,HUMAN-IMMUNODEFICIENCY-VIRUS,NATURAL-HISTORY,PROTEASE INHIBITORS,DISEASE PROGRESSION,HIV,THERAPY,hyaluronic acid,hepatitis C virus}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{577--587}},
  title        = {{Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis}},
  url          = {{http://dx.doi.org/10.1097/QAD.0000000000000069}},
  volume       = {{28}},
  year         = {{2014}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: